HMN 2025: How to pinpoint keys to cell remedy response for leukemia

Dana-Farber Cancer Institute researchers have recognized elements that decide whether or not donor lymphocyte infusion (DLI), a normal remedy for sufferers with acute myeloid leukemia (AML) who’ve relapsed after allogenic hematopoietic stem cell transplant, will efficiently transfer the affected person into remission. The workforce recognized {that a} key cell sort within the DLI product and options of the tumor microenvironment in sufferers each play a task.

The findings had been printed in Science Immunology.

“Relapse of AML after stem cell transplant is a significant problem,” says first creator Katie Maurer, MD, Ph.D.. “There are few efficient therapies, and affected person outcomes after relapse are poor.”

For sufferers with AML, a stem cell transplant holds the potential for a remedy. The objective of the transplant is to switch the affected person’s hematopoietic stem cells—cells that rejuvenate provides of blood and immune cells—with donor stem cells that aren’t cancerous. In addition, the donor cells additionally embrace energetic immune cells that may assault leukemia cells that stay within the affected person after the transplant. This phenomenon is named the graft versus leukemia impact.

However, roughly one in three sufferers with AML relapse after allogenic stem cell transplant. DLI is a follow-on remedy that may assist stave off or deal with relapse. It includes an infusion of white blood cells, known as lymphocytes, from the donor of the stem cell transplant into the affected person.

DLI is profitable in solely about 15-20% of sufferers with AML. Further, precisely how the cells within the DLI product assist transfer leukemia into remission should not recognized, making it tough for investigators to enhance the remedy.

Maurer and principal investigator Catherine Wu, MD, chief of Dana-Farber’s Division of Stem Cell Transplantation and Cellular Therapies, wished to be taught extra about what elements contribute to the success of DLI. To do that, they examined cells from the bone marrow of 25 sufferers with relapsed leukemia who had been handled with stem cell transplant and DLI. The pattern included sufferers who responded to DLI and sufferers who didn’t.

They employed single cell sequencing strategies to deeply profile multitudes of cells from every affected person. This enabled the workforce to be taught not solely the vary of cell sorts within the bone marrow, but in addition how these cells had been interacting and driving immune responses within the affected person.

The discovered that sufferers who responded to DLI remedy had notably completely different mobile populations of their bone marrow in comparison with sufferers who didn’t reply. The discovering means that there could be types of AML which might be “sizzling,” that means they reply to immune remedy, or “chilly,” that means they don’t, much like the “sizzling” and “chilly” paradigm seen in some strong tumors.

The workforce additionally recognized a single immune cell sort that seems to mediate the graft versus leukemia impact in sufferers that reply to DLI. The cell sort, CD8⁺ cytotoxic T lymphocytes that categorical a transcription issue known as ZNF683/Hobit at excessive ranges, seem to coordinate with different immune cells to increase and assault leukemia cells. In sufferers who didn’t reply, these T cells had decrease ranges of expression of ZNF683/Hobit and better ranges of markers that inhibit their exercise.

Further, the workforce discovered that this cell sort originates within the DLI product. That is, it’s current within the donor’s authentic graft and re-infused throughout DLI.

“The objective of our analysis is to establish the methods during which some sufferers reply, within the hopes that uncovering these mechanisms will help us create improved therapies which might be more practical for a better variety of sufferers,” says Maurer. “In this challenge, we recognized a selected subset of activated T cells which have anti-leukemic exercise. This discovery paves the way in which for creation of T cell therapies with improved efficacy in treating AML.”